Most people who struggle on semaglutide aren’t failing because the medication doesn’t work. They’re failing because they don’t understand the dosing protocol. They start too high, increase too fast, or stay too long at a dose that isn’t moving the needle anymore.
Semaglutide dosing for weight loss follows a structured escalation called titration. You start low, increase gradually every 4 weeks, and find the dose your body responds to best. The starting dose is 0.25 mg per week. The standard maintenance dose is 1.7 mg to 2.4 mg weekly. The FDA-approved maximum for weight loss as of 2026 is 2.4 mg per week for standard Wegovy, with a newly approved 7.2 mg dose for appropriate patients.
This guide covers the complete dosing schedule, what each dose phase actually does, the difference between units and milligrams for compounded semaglutide, and what you can realistically expect at each dose level based on clinical evidence.
This is the standard titration schedule used for branded semaglutide (Wegovy) and mirrored closely in most compounded semaglutide programs. Your provider may adjust this based on your side effects, response, and specific formulation.
| Weeks | Dose (mg/week) | Purpose |
| Weeks 1–4 | 0.25 mg | Starter dose; tolerance building |
| Weeks 5–8 | 0.5 mg | Adjustment phase; appetite suppression begins |
| Weeks 9–12 | 1.0 mg | Active fat loss begins; meaningful results |
| Weeks 13–16 | 1.7 mg | Advanced fat loss; increased GLP-1 effect |
| Week 17+ | 2.4 mg | Maintenance dose; maximum standard effect |
Each increase happens approximately every 4 weeks, though your provider may keep you at a lower dose longer if you’re achieving good results or managing side effects. There’s no clinical benefit to rushing up the ladder.
For compounded semaglutide programs like InjectCo’s semaglutide delivery program at $249/month, the titration schedule mirrors this structure with doses adjusted based on your monthly check-in results.
The starting dose of semaglutide is always 0.25 mg once weekly. No exceptions. This isn’t arbitrary.
The 0.25 mg starting dose exists for one reason: to let your digestive system adapt to the medication before increasing the GLP-1 effect. Semaglutide slows gastric emptying, which means food moves through your stomach more slowly. That effect is what reduces appetite and creates the calorie deficit that drives weight loss. But if you hit your system with a full therapeutic dose immediately, the GI side effects can be severe. Nausea, vomiting, diarrhea, and reflux are the most common complaints, and they’re dose-dependent. Starting at 0.25 mg keeps those effects manageable while your body adjusts.
Clinicians are clear on this point: “No, you should never start semaglutide at a higher dose. The titration schedule is a critical safety measure, and the 0.25 mg dose is intended to be the starter dose.” Rushing the starting dose doesn’t produce faster weight loss. It produces more side effects and more dropout.
The 0.25 mg dose isn’t a therapeutic dose. You won’t lose significant weight at 0.25 mg. That’s expected. This phase is preparation, not treatment.
The dose escalation schedule in semaglutide treatment isn’t just about managing side effects. There’s a biological rationale for why dosing builds over time.
At each dose increase, semaglutide produces stronger GLP-1 receptor activation. That means:
Your body also develops a tolerance to the GI side effects over time, which is why patients who start carefully can tolerate higher doses later in treatment that would have been overwhelming at week one.
This question has a more complex answer in 2026 than it did a year ago.
The standard FDA-approved maximum dose of semaglutide for chronic weight management is 2.4 mg per week (Wegovy). For Ozempic used for type 2 diabetes, the maximum is 2 mg per week.
But as of March 2026, the FDA approved a higher dose of semaglutide at 7.2 mg per week for appropriate patients. This approval followed the STEP UP trial, a Phase 3b study published in The Lancet Diabetes & Endocrinology in 2025, which evaluated the 7.2 mg weekly dose in over 1,400 adults with obesity and without diabetes. The results were significant. Patients on 7.2 mg lost an average of 20.7% of their starting body weight over 72 weeks, compared to 17.5% with the standard 2.4 mg dose. Around one-third of patients achieved 25% or greater weight loss at the higher dose.
For most patients in standard medically supervised programs, 2.4 mg remains the target maintenance dose. The 7.2 mg option is relevant for patients who plateau on standard dosing and whose providers determine the higher dose is clinically appropriate.
Not every patient needs to reach 2.4 mg to see clinically meaningful results. This is one of the most important things to understand about semaglutide.
The STEP clinical trials showed that at 2.4 mg, average weight loss was 14.9% of starting body weight over 68 weeks. At 1.0 mg (used in STEP 2 as the lower comparison arm), average weight loss was 7.0%. Both are significant improvements over placebo results of 2.4%.
What this means practically: if you’re achieving your weight loss goals and tolerating the medication well at 1 mg or 1.7 mg, there’s no requirement to push to 2.4 mg. The higher dose produces better outcomes on average, but individual response varies substantially.
Here’s a realistic range of what patients experience by dose level, based on clinical and real-world data:
| Dose | Expected Average Weight Loss (68 weeks) | Notes |
| 0.25 mg | Minimal (starter only) | Tolerance phase, not therapeutic |
| 0.5 mg | 2–4% | Early appetite effects begin |
| 1.0 mg | 7–8% average | Meaningful for many patients |
| 1.7 mg | 10–12% average | Significant results for most |
| 2.4 mg | 14.9% average | Standard maximum for most programs |
| 7.2 mg (new) | 20.7% average (STEP UP trial) | For appropriate patients, new in 2026 |
The sweet spot for many patients falls between 1.0 mg and 1.7 mg. This is where appetite suppression is significant, GI side effects are manageable, and meaningful fat loss is occurring without the additional complexity of pushing to maximum dose.
Your provider’s job is to help you find that optimal dose for your body, not to automatically push you to the highest possible number.
What happens when you hit your target weight? This is where most patients and many providers get the strategy wrong.
Semaglutide works by maintaining an active hormonal signal that suppresses appetite and regulates blood sugar. When you stop the medication, that signal disappears. The biological drivers of obesity, specifically the hunger hormones and metabolic set points that pushed your weight up in the first place, come back. Studies show that most patients regain a significant portion of lost weight within 1 to 2 years of discontinuing semaglutide without a structured transition plan.
The better approach for most patients is a maintenance phase at a reduced dose, not abrupt discontinuation.
After reaching goal weight, many providers reduce the dose to the lowest effective level that maintains appetite suppression and metabolic benefit. For some patients, that might be 0.5 mg per week. For others, 1.0 mg. The goal is to find the minimum dose that keeps the weight stable without unnecessary medication load.
This maintenance approach, combined with the dietary and lifestyle habits built during active weight loss, gives patients the best chance of long-term success. At InjectCo’s BriteBody weight loss program, monthly check-ins allow providers to adjust dosing based on where you are in your weight loss journey, including transitioning to a maintenance phase at the right time.
Compounded semaglutide is a version of the medication prepared by a licensed compounding pharmacy rather than a pharmaceutical manufacturer. InjectCo’s program at $249/month uses compounded semaglutide, delivered monthly to patients’ doors or picked up at any of 8 Texas locations.
The titration schedule for compounded semaglutide mirrors the branded protocol: start at 0.25 mg, increase every 4 weeks. The key differences are in how the medication is packaged and administered.
Branded semaglutide (Wegovy, Ozempic) comes in pre-filled pens with fixed dose settings. You dial to your prescribed dose and inject. The pen handles the measurement.
Compounded semaglutide typically comes in a vial with a separate insulin syringe. You draw the prescribed volume from the vial. This requires understanding the concentration of your specific formulation to draw the right amount.
Common compounded semaglutide concentrations include 2.5 mg/mL and 5 mg/mL, though concentrations vary by pharmacy. Your clinic will provide a specific dosing guide for your vial. Do not use another clinic’s conversion chart with your vial because the math won’t match.
Compounded semaglutide often includes vitamin B12 in the formulation. B12 doesn’t affect the semaglutide dosing. It’s an additional ingredient that rides along in the same injection volume.
This is the most common point of confusion among patients on compounded semaglutide, and it’s also the most important to get right. The wrong calculation is a patient safety issue.
Semaglutide is prescribed in milligrams (mg). But when using a vial and insulin syringe for compounded formulations, you draw the medication in units. The conversion between mg and units depends entirely on the concentration of your specific vial.
The formula: Units = (Dose in mg ÷ Concentration in mg/mL) × 100
Here’s how the same 0.25 mg dose looks at different concentrations:
| Vial Concentration | Prescribed Dose | Units to Draw |
| 1 mg/mL | 0.25 mg | 25 units |
| 2.5 mg/mL | 0.25 mg | 10 units |
| 5 mg/mL | 0.25 mg | 5 units |
A patient drawing 10 units at one concentration gets a completely different milligram dose than a patient drawing 10 units at a different concentration. This is why you must always confirm your vial’s labeled concentration before every injection, and why your provider gives you a specific chart for your specific vial, not a generic one.
Never attempt to calculate your own unit conversion without confirming your exact vial concentration. Never use conversion information from another clinic’s materials unless it explicitly matches your vial label. Your InjectCo provider will walk you through exactly how to draw your dose at your monthly check-in.
Semaglutide is a once-weekly injection. The same day every week is the standard schedule because semaglutide’s half-life is approximately one week. Consistency keeps blood levels stable.
Here’s what the weekly schedule looks like in practice:
Injectable and oral semaglutide both use the same active molecule, but the dosing structure is completely different.
Injectable semaglutide (Wegovy, Ozempic, compounded):
Oral semaglutide (Rybelsus for diabetes):
InjectCo’s sublingual semaglutide drops follow a different protocol from both of the above. They’re taken once daily (not weekly) and are placed under the tongue 30 minutes before the first meal. The drops are an alternative for patients who prefer to avoid needles entirely. Pricing for sublingual semaglutide drops at InjectCo is $425/month.
The main practical difference between injectable and oral delivery: injectable semaglutide has more predictable absorption because it bypasses the digestive tract. Oral semaglutide bioavailability is much lower because stomach acid degrades a significant portion before it can be absorbed. This is why oral doses are expressed in larger milligram numbers even though less of the drug reaches the bloodstream per dose.
Clinical trials give averages. Real-world results add context. Here’s what patients typically experience at each phase of treatment:
0.25 mg (weeks 1–4): Most patients report little to no appetite change. Mild nausea in the first week is common. No significant weight loss expected. This is the adaptation phase.
0.5 mg (weeks 5–8): Appetite begins to shift. Many patients report feeling full faster and having fewer cravings between meals. Average weight loss at this stage is typically 2 to 4 pounds total. GI side effects usually start to settle.
1.0 mg (weeks 9–12): This is where most patients notice a real change in their relationship with food. The clinical term is appetite suppression, but patients describe it as “food just doesn’t sound as appealing.” Average weight loss at 68 weeks in clinical trials at this dose level was approximately 7% of starting body weight.
1.7 mg (weeks 13–16): Significant appetite suppression for most patients. Clinical data shows 10 to 12% average body weight reduction at this dose over the full treatment period.
2.4 mg (week 17+): The standard maintenance dose. The STEP 1 trial showed an average weight loss of 14.9% of starting body weight over 68 weeks at this dose. 86.4% of participants lost 5% or more of their weight. 50.5% lost 15% or more.
A real patient scenario: someone starting at 220 pounds and reaching 2.4 mg maintenance could expect to lose between 22 and 40 pounds over a full treatment course of 68 weeks, based on clinical averages. Individual results vary based on diet, activity, metabolic rate, and consistency.
Semaglutide carries an FDA boxed warning for a potential risk of thyroid C-cell tumors. The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. These aren’t minor considerations. They require a thorough medical history review before any prescription is written.
Beyond contraindications, medical supervision matters for semaglutide dosing because individual response varies significantly. Some patients tolerate aggressive titration well. Others need to stay at a lower dose for 8 or 12 weeks before their body adjusts enough to step up. Without a provider monitoring your response, you either rush the process (more side effects, higher dropout) or stagnate at a dose that isn’t producing results anymore.
The biggest risks of unsupervised semaglutide use:
Medical supervision isn’t just a formality. For a medication this effective at altering how your body processes hunger hormones, it’s the difference between good results and an avoidable complication.
InjectCo’s BriteBody weight loss program combines physician-guided prescription, monthly check-ins, and personalized dosing adjustments from licensed nurse practitioners and physician assistants who specialize in GLP-1 weight management.
Here’s what the program includes:
You may qualify for InjectCo’s semaglutide program if:
Ready to start? Book a free virtual consultation at injectco.com or text (817) 533-7676. Same-day appointments available 8 AM to 8 PM, seven days a week.
You can also learn more about semaglutide injection sites and best injection practices to prepare for your first dose.
How much semaglutide should I take for weight loss?
The starting dose is always 0.25 mg once weekly. Your provider will increase your dose every 4 weeks through 0.5 mg, 1.0 mg, 1.7 mg, and potentially 2.4 mg based on your response and side effect tolerance. Never self-adjust your dose without provider guidance.
Is 1 mg of semaglutide enough for weight loss?
For many patients, yes. Clinical trials showed average body weight loss of approximately 7% over 68 weeks at the 1.0 mg dose. If you’re achieving meaningful results at 1.0 mg with good tolerability, your provider may decide the higher dose isn’t necessary for you. Not everyone needs to reach 2.4 mg.
What is the highest dose of semaglutide?
As of 2026, the FDA-approved maximum for Wegovy (weight management) is 7.2 mg per week, newly approved in March 2026. The standard maintenance target for most programs remains 2.4 mg weekly. The 7.2 mg dose is for patients who plateau on standard dosing under specific clinical criteria.
What is the lowest dose of semaglutide?
The starting dose is 0.25 mg once weekly. This is a tolerance-building dose, not a therapeutic one. Most providers prescribe a minimum of 0.5 mg or higher once the body has adjusted.
How long before you increase your semaglutide dose?
Dose increases happen every 4 weeks following the standard titration schedule. Some providers extend each step to 6 or 8 weeks if a patient is managing GI side effects or achieving strong results at a given dose. Never increase your dose sooner than 4 weeks without explicit provider instruction.
Is 0.25 mg of semaglutide the same as 8 units in a compounded vial?
It depends entirely on the concentration of your specific vial. At 5 mg/mL, 0.25 mg equals 5 units. At 2.5 mg/mL, 0.25 mg equals 10 units. At 1 mg/mL, 0.25 mg equals 25 units. Always use the instructions provided with your specific prescription.
What happens if I miss a semaglutide dose?
If your next scheduled dose is more than 2 days away, take the missed dose as soon as possible. If it’s less than 2 days away, skip the missed dose and resume your normal schedule. Never take two doses to make up for a missed one. If you’re unsure, contact your provider before injecting.
Can you take semaglutide every other week?
No. Semaglutide is designed and clinically tested for once-weekly administration. Taking it every other week isn’t supported by evidence and will reduce treatment effectiveness. If cost or access is a concern, discuss your options with your provider rather than self-adjusting your schedule.
Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Semaglutide is a prescription medication with an FDA boxed warning. Dosing must be supervised by a licensed healthcare provider. Never adjust your dose without provider guidance. This article does not create a provider-patient relationship.
